INTRODUCTION
No substantive therapeutics are available for the treatment of almost any form of disease entailing nerve cell death. Patients suffering from any of a wide spectrum of neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, fronto-temporal dementia, and Huntington's disease are condemned to progressive demise of the CNS by virtue of nerve cell death. It is likewise the case that no effective treatments exist for injuries to the brain or peripheral nervous system, including traumatic or concussive brain injury, spinal cord injury, or peripheral nerve injury. Any chemical having the capacity to safely impede nerve cell death in the context of these varied diseases or injuries would offer the opportunity for transformative impact in modern medicine.
Previously, we performed a target-agnostic, in vivo screen in search of chemicals that might enhance hippocampal neurogenesis in adult mice (Pieper et al., 2010) . The screen was simple in concept. We selected 1,000 drug-like chemicals from the 250,000 compounds in the University of Texas Southwestern Medical Center (UTSWMC) high-throughput screening center. The compounds were selected to preserve chemical diversity, enhance the representation of chiral molecules, and avoid untoward chemical properties such as reactive moieties. The 1,000 molecules were randomly pooled into groups of ten, and each pool was administered directly into the left ventricle of two adult mice. Intracranial delivery was facilitated by stereotactic positioning of a canula fed directly by an Alzet minipump containing the mixture of ten chemicals. The drug mixture was administered over a week-long period at concentrations anticipated to deliver midnanomolar levels of the ten test compounds. Daily injections of the thymidine analog, bromodeoxyuridine (BrdU), were coadministered in order to monitor the formation of new hippocampal nerve cells. Following compound administration, animals were sacrificed such that brain tissue could be recovered, sectioned, and stained with antibodies to BrdU. This 2-year screen led to the discovery of a handful of pools that enhanced neurogenesis in both test mice that had been exposed to the pool. Breakdown of the active pools allowed the individual testing of each of the ten chemicals in the pool, leading to the discovery of eight proneurogenic compounds (Pieper et al., 2010) .
Among the eight proneurogenic chemicals, pharmacological testing gave evidence that only one of the compounds had favorable pharmacological properties. Pool seven (P7) contained an aminopropyl carbazole as its active, third compound (C3). When administered to mice via intraperitoneal, intravenous, or oral routes, the P7C3 compound revealed favorable half-life, volume of distribution, and brain penetration. It was also found that P7C3 could be safely administered to mice and rats for prolonged periods at concentrations well above those required to stimulate hippocampal neurogenesis, giving evidence that the molecule was not overtly toxic to rodents.
Although it was initially anticipated that proneurogenic compounds would act by stimulating the mitotic birth of newborn nerve cells in the subgranular layer of the dentate gyrus, P7C3 revealed no such activity. The 2-fold enhanced level of BrdUpositive neurons observed over a week-long dose of P7C3 was absent when animals were pulsed with BrdU for only 24 hr. More strikingly, when BrdU was pulsed for only 1 day and animals were subsequently administered P7C3 for 1 month, we observed a far larger enhancement in BrdU-positive hippocampal neurons (500%). Instead of stimulating the mitotic division of neuronal stem cells, these observations gave evidence that P7C3 mitigated the death of newborn neurons. Under the conditions of our study, only 10%-20% of newborn neurons survive the month-long differentiation process to become properly wired hippocampal neurons. Prolonged administration of P7C3 significantly mitigated the death of newborn neurons, such that upward of half of the cells survive the month-long ''differentiation gauntlet'' taking place between stem cell mitosis and terminal nerve cell differentiation. Indeed, localized expression of proapoptotic proteins in newborn neurons has been found to limit neurogenesis, whereas expression of antiapoptotic proteins enhances neurogenesis in adult mice (Kim et al., 2009; Kuhn et al., 2005; Sun et al., 2004) . It has likewise been found that the proneurogenic benefits of wheel running and/or enriched environment for caged rodents is primarily attributable to neuroprotective effects on newborn hippocampal neurons (Kempermann et al., 1997; Kim et al., 2010; van Praag et al., 1999) .
Having discovered the aminopropyl carbazole chemical in an unbiased, in vivo screen and having found that it protects newborn neurons from death, we use methods of medicinal chemistry to improve the potency and pharmacological properties of P7C3 (MacMillan et al., 2011; Naidoo et al., 2014; Pieper et al., 2014) . Using these improved, active derivatives of P7C3, we have observed neuroprotective activity in animal models of Parkinson's disease (De Jesú s-Corté s et al., 2012), amyotrophic lateral sclerosis , as well as concussive injury to the rodent brain (Yin et al., 2014) . Of significant concern, however, was the fact that we have been ignorant of the mechanism of action of the P7C3 class of neuroprotective chemicals. Here, we provide evidence that these chemicals function by enhancing the activity of the rate-limiting enzyme in the salvage of nicotinamide adenine dinucleotide (NAD) from nicotinamide.
RESULTS

Active Variants of P7C3 Protect Cultured Cells from Doxorubicin-Mediated Toxicity
Progress on studies aimed toward resolving the mode of action of P7C3 has been hampered by the fact that we have been limited to studies of drug action in living animals. Our standard assay of neurogenesis requires, under optimal conditions, a 1 month turnaround from the synthesis of a new derivative to a score for its neuroprotective activity. In efforts to break this logjam, we tested whether P7C3 might have cell-protective activity to any of eight generic toxins. The active A20 variant of P7C3 was found to protect cultured U2OS cells from doxorubicin-mediated toxicity ( Figure 1A ). By contrast, no evidence of drug-mediated protection was observed for any of seven other toxins ( Figure S1 available online). Furthermore, as judged by the DNA damage marker-phosphorylation of H2AX and the hallmark of apoptosis-caspase-3 activation, coadministration of A20 blocked doxorubicin-induced apoptosis, but not DNA damage response ( Figure S2 ).
In order to assess whether a correlation might exist between proneurogenic activity in living mice and doxorubicin toxicity (dox:tox) protection, we assayed 224 compounds that have See also Figures S1, S2, and S3 and Tables S1 and S2. been synthesized and assayed for proneurogenic activity over the past 4 to 5 years (Table S1 ). These include hundreds of structure:activity relationship derivatives of P7C3, as well as a number of tricyclic antidepressants reported in the literature to have proneurogenic activity (Malberg et al., 2000) . P7C3 derivatives were the only molecules having dox:tox protective activity ( Figure S3 ; Table S2 ). Further inspection of the data revealed that the chemical features of the carbazole ring, length of the aliphatic linker, and nature of the aromatic ring were all important determinants for both proneurogenic activity and dox:tox protection. Perhaps most compellingly, it was observed that the (À)-P7C3-S243 enantiomer that was active in the in vivo neurogenesis assay (Naidoo et al., 2014) , the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of Parkinson's disease (Naidoo et al., 2014) , and the concussive blast injury model (Yin et al., 2014) was also protective in the dox:tox assay ( Figure 1B ). By contrast, the (+)-P7C3-S243 enantiomer that was far less active in the three in vivo assays of neuroprotection was also considerably less active in the dox:tox protection assay. From these observations, we conclude that active derivatives of P7C3 function by a related mechanism to protect neurons in living animals as well as cultured U2OS cells exposed to doxorubicin.
Identification of p70 and p55 as Intracellular Targets of P7C3
Various methods have been employed in efforts to identify the intracellular target of P7C3, including biotinylation followed by affinity purification, radiolabeling followed by filter-binding assays, and photocrosslinking. Among these strategies, the photocrosslinking approach has been uniquely successful. P7C3-S326 was prepared to contain both a benzophenone for photocrosslinking and an alkyne moiety for use in click chemistry ( Figure 2A ). This derivative was found to be active in both the in vivo neurogenesis assay and the dox:tox assay. When incubated with cultured cells, the P7C3-S326 derivative became covalently attached to roughly a dozen proteins. Among the covalently modified proteins, only one could be competed when the cells were coincubated with a 303 excess of the active A20 variant of P7C3. This polypeptide exhibited an apparent molecular mass of 70 kD ( Figure 2B ).
Binding competition assays were conducted with 168 chemical derivatives of P7C3 as a means of testing whether there might be a correlation between dox:tox protection and binding competition ( Figure S4 ). The scatter plot shown in Figure 2D revealed a statistically significant correlation between the two activities, yielding a p value of 9.4 3 10
À20
. It can thus be predicted with a high level of confidence that active variants of P7C3 are able to compete for P7C3-S326 crosslinking but that inactive variants cannot. Armed with this knowledge, cell fractionation experiments were performed in order to enrich for the p70 band. During the course of these studies, it was periodically observed that P7C3-S326 could also be crosslinked to a second band running with an apparent molecular weight of 55 kD. Just as was the case for p70, active variants of P7C3 competed for Figure S4 . (C) Formulas used for calculating doxorubicin toxicity (dox:tox) protection activity. Protection activity is expressed by (Sinf-S0)/AC50 in the 12-point dose response curve (DRC) corresponding to each compound, wherein both efficacy and potency of compounds were considered. Sinf represents the expected maximal protection. S0 is the baseline. AC50 is the concentration of a compound where 50% of its maximal protection effect was observed. See also Figure S3 and Table S2 .
(D) Scatterplot of 168 derivatives of P7C3 revealed a significant correlation between protective activity of P7C3 analogs from doxorubicin-mediated toxicity and their ability to compete for photocrosslinking of P7C3-S326 to p70. In the photocrosslinking assays, the p70 band intensity was quantified by Image J and compared the sample of P7C3-S326 alone with that of P7C3-S326 plus competitor. Pearson correlation coefficient (r) and two-tailed p value were determined by GraphPad Prism 6 and Spearman Rank Correlation (v1.0.1) software. See also Table S1. p55 binding, whereas inactive variants did not. Moreover, both proteins copurified with a cellular fraction following centrifugation at 12,000 g.
The p70 and p55 Targets of P7C3 Correspond to Nicotinamide Phosphoribosyltransferase
Partially purified protein preparations were resolved by 2D gel electrophoresis. In order to discriminate between protein spots competed by an excess of the active, A20 variant of P7C3 and those that were not, separate lysates were prepared from cells that had been coexposed to the P7C3-A20 competitor or not. Click chemistry was used to append a red fluorescent dye onto P7C3-S326-modified proteins of the former lysates (Kolb et al., 2001 ). The latter lysates were modified by a green dye, such that in imaging 2D gels, we could focus on green protein spots and avoid spots labeled by both green and red dyes. Such efforts led to the identification of green-only spots migrating at either 70 kD or 55 kD ( Figures 3A-3C ). Proteins of both molecular weights migrated in the isoelectric focusing dimension at four closely spaced pH positions. This electrophoretic behavior might be consistent with posttranslational modifications of the same protein, leading to different isoforms bearing slight differences in ionic charge. Perplexingly, the pattern of charge distribution was identical for the 70 kD and 55 kD polypeptides.
The eight green-only spots, four from p70 and four from p55, were then picked and subjected to shotgun mass spectrometry for protein identification. All four of the p55 spots yielded by far the highest number of spectral counts for nicotinamide phosphoribosyltransferase (NAMPT) ( Table S3 ). Both the predicted size (55 kD) and isoelectric point (pH 6.7) of NAMPT match spots 1-4 picked from the 2D gel. Likewise, mass-spectrometry-based analysis gave substantive percentage coverage levels of 12%, 82%, 38%, and 62% for the NAMPT enzyme in spots 1-4 (Table  S3) . By contrast, no proteins could be identified above the false discovery rate for the four p70 spots. Poststaining of the 2D gel Lysates from cells exposed to 0.3 mM P7C3-S326 were CLICKed with a green dye, Alexa 532, and those from cells coexposed to 0.3 mM P7C3-S326 and 5 mM of the active competitor P7C3-A20 were CLICKed with a red dye Cy5.
(A and B) CLICK-reacted lysates were combined, subjected to 2D gel electrophoresis, and scanned in the green channel (A) and the red channel (B). (C) Images from both channels were merged to reveal green-only spots.
(D) After spot picking, total proteins were visualized by Sypro Ruby staining. White circles indicate spots excised for shotgun mass spectrometry analysis. See also Table S3 .
with Sypro ruby dye showed prominent protein staining for all four of the p55 spots and no staining for any of the four p70 spots ( Figure 3D ). Apparently, despite equivalent photocrosslinking by P7C3-S326, the molar ratio of drug modification of p70 must be at least three orders of magnitude greater than p55.
The perplexing relationship between p70 and p55 was clarified upon adding 7 M urea to the SDS-PAGE gels used to resolve the two bands. In the absence of urea, almost all of the S326-modified material migrated as the p70 band. Addition of urea to the gel converted all of the labeled material to the p55 band ( Figure 4A ). By running a gel crafted to contain a horizontal gradient of urea, 7 M on the right and no urea on the left, it was possible to observe graded conversion of p70 into p55 ( Figure 4B ). These observations give evidence that, when NAMPT is covalently bound by P7C3-S326, it can adopt an anomalous pattern of electrophoretic migration under gel conditions that are not fully denaturing.
Active Derivatives of P7C3 Restore NAD Levels in Doxorubicin-Treated Cells Having observed P7C3-S326 crosslinking to both the p70 and p55 forms of NAMPT, we wondered whether active variants of P7C3 might modify the activity of the enzyme. The NAMPT enzyme controls the rate-limiting step in the NAD salvage pathway (Preiss and Handler, 1958) . NAMPT is an obligate dimer whose molecular structure has been resolved by X-ray crystallography (Khan et al., 2006; Wang et al., 2006) . On the basis of molar ratio of crosslinking, P7C3-S326 strongly prefers the p70 isoform of NAMPT relative to the p55 isoform. Hypothesizing that p70 represents a drug-altered form of NAMPT, we tested whether the highly active P7C3-A20 variant might either enhance or reduce NAD levels in living cells.
Doxorubicin is a DNA-damaging toxin known to activate the poly-ADP-ribose polymerase (PARP) enzyme as a central feature of DNA repair (Muñ oz-Gá mez et al., 2009; Pacher et al., 2002) . PARP uses NAD as the donor for poly-ADP-ribose synthesis and hence lowers cellular levels of NAD. U2OS cells exposed to sublethal levels of doxorubicin were subjected to metabolite analysis by mass spectrometry, allowing simultaneous, quantitative analysis of hundreds of intracellular metabolites (Tu et al., 2007; Wang et al., 2009) . As expected, doxorubicin treatment led to a significant decline in NAD levels relative to all other metabolites assayed. Coadministration of the A20 variant of P7C3 led to a dose-dependent replenishment of NAD ( Figure 5A ). The mass spectrometry methods used to quantitate metabolite levels measured NAD relative to hundreds of other intracellular metabolites. As such, the ability of the A20 variant of P7C3 to restore intracellular levels of NAD does not simply reflect the generalized health of cells but instead reflects the relative increase in NAD levels compared with hundreds of other metabolites.
A more facile method of quantifying the NAD analyte, employing the commercially available ''NAD/nicotinamide adenine dinucleotide, reduced form (NADH)-Glo'' kit, confirmed P7C3-A20-mediated rebound of NAD levels in doxorubicin-treated U2OS cells. We also observed NAD rebound for the racemic mix of the active P7C3-S243 compound but no rebound at all for the inactive P7C3-S6 and P7C3-S117 compound variants ( Figure 5B ). This method of assay was used to test 159 variants of P7C3 that had been used to query the correlative relationship between dox:tox protection and competition in the P7C3-S326 crosslinking assay (Table S1 ; Figure 2D ). Each chemical variant of P7C3 was coincubated with doxorubicin on cultured U2OS cells at five doses, and cells were assayed for intracellular levels of NAD ( Figure S5 ; Table S2 ). The scatterplot shown in Figure 5C reveals exceptional concordance between the dox:tox protective activities of the 159 compounds and their relative abilities to enhance NAD levels (correlative p value of 1.8 3 10 À35 ).
NAMPT is the rate-limiting enzyme in the salvage pathway whereby cells sequentially convert nicotinamide into nicotinamide adenine mononucleotide (NMN) and NAD (Preiss and Handler, 1958) . If active variants of P7C3 indeed bind to the NAMPT dimer in a manner fostering its activity, then these compounds should enhance the flux of nicotinamide through the salvage pathway. To test this hypothesis, 14 C-labeled nicotinamide was administered to cultured U2OS cells that were pretreated with doxorubicin and assayed by thin-layer chromatography followed by autoradiography. As shown in Figure 6 , enhanced conversion of radiolabeled nicotinamide into NMN and NAD was observed in a dose-responsive manner upon exposure of cultured U2OS cells to the active, A20 variant of P7C3. Upon examining if P7C3 derivatives might elevate NAD levels in naive cells (without doxorubicin pretreatment), we failed to observe any compound-mediated effect on NAD levels.
Active Variants of P7C3 Enhance the Activity of the Purified NAMPT Enzyme A recombinant form of the human NAMPT enzyme was cloned, expressed, and purified according to published conditions (Khan et al., 2006; Wang et al., 2006) . The enzymatic activity of recombinant NAMPT was monitored in a coupled assay wherein nicotinamide conversion to NMN was followed by sequential production of NAD (via the nicotinamide mononucleotide adenylyl-transferase [NMNAT] enzyme) and NADH (via alcohol dehydrogenase). As shown in Figure 7A , the A20 variant of P7C3 activated the enzyme reaction in a dose-dependent manner. No activation of NADH production was observed when NAMPT was eliminated from the reaction, giving evidence that enhancement did not result from compound effects on either NMNAT or alcohol dehydrogenase ( Figure S6 ).
Two additional experiments were conducted to investigate activation of the recombinant NAMPT enzyme. First, 30 derivatives of P7C3 having varied activity were tested for enzyme activation. The ability of the 30 variants to activate NAMPT in the coupled enzyme assay was then correlated on scatter plots to three other measures of compound activity: (1) ability to protect cultured cells from doxorubicin toxicity; (2) ability to compete with photocrosslinking by P7C3-S326 in living cells; and (3) ability to restore NAD levels in doxorubicin-treated cells ( Figure 7B) . In all cases, statistically significant evidence of correlation was observed. Second, we compared the activities of the racemic mix of P7C3-S243, the (À)P7C3-S243 enantiomer and the (+)P7C3-S243 enantiomer in NAMPT enzyme assay. As shown in Figure 7C , the (À)P7C3-S243 enantiomer was more active in stimulating NAMPT than the racemix mix, which-in turn-was more active than the (+)P7C3-S243 enantiomer. This same hierarchy of activity has been observed in all in vivo assays tested to date, including adult neurogenesis, and the MPTP model of Parkinson's disease (Naidoo et al., 2014) , concussive blast injury (Yin et al., 2014) , protection of cultured cells from doxorubicinmediated activity (Figure 1 ), and rebound of NAD levels in doxorubicin-treated cells (Table S1 ). Finally, we tested whether the recombinant NAMPT enzyme could be photocrosslinked to P7C3-S326. As shown in Figure S7 , P7C3-S326 binds directly to NAMPT in a manner competed by active variants of P7C3 (P7C3-A20 and P7C3-S243), but not by the inactive P7C3-S87 variant.
DISCUSSION
Why is it that active variants of P7C3 are able to protect cultured cells from doxorubicin-mediated toxicity, in the face of no protective activity against seven other toxins? Three observations now help understand this selectivity. First, doxorubicin reduces (B) Active derivatives P7C3-A20 and P7C3-S243, but not inactive derivatives P7C3-S6 or P7C3-S117, facilitate replenishment of NAD levels in doxorubicin-treated cells. Cells were grown in 96-well plates and treated with the indicated concentrations of P7C3-A20, P7C3-S243, P7C3-S6, or P7C3-S117 together with 0.5 mM doxorubicin for 45 hr. Cellular NAD abundance was determined by NAD/NADH Glo assay kit. The data are represented as the mean ± SD of experimental duplicates. See also Figure S5 and Table S2 . (C) Scatterplots revealed a strong correlation between dox:tox protective activities of 159 compounds and their relative abilities to replenish NAD levels. The activities in both assays are represented by (Sinf-S0)/AC50 in dose response curves of test compounds. See also Table S1. intracellular levels of NAD, likely via activation of PARP. Second, active variants of P7C3 protect cultured cells from dox:tox, likely by stimulating a rebound in the intracellular levels of NAD. Third, active variants of P7C3 enhance the activity of the purified, recombinant NAMPT enzyme. We conclude that the dox:tox protective activity of our aminopropyl carbazole chemicals is directly reflective of their ability to enhance the salvage pathway whereby nicotinamide is converted to NAD. Our findings are consistent with earlier reports that programmed enhancement in the expression of the NAMPT enzyme protects mammalian cells against genotoxic stress (Yang et al., 2007) and extends the life span of budding yeast (Anderson et al., 2002) .
The target-agnostic in vivo screen performed years ago led, in an unbiased manner, to the P7C3 class of neuroprotective chemicals (Pieper et al., 2010) . We now hypothesize that the neuroprotective efficacy of our aminopropyl carbazole chemicals can be attributed to their ability to foster salvage of NAD from nicotinamide. This interpretation is concordant with an equally unbiased series of forward genetic studies performed over the past three decades. In the 1980s, scientists working in Oxford, England described a variant strain of mice that impedes Wallerian degeneration, designated the Wallerian degeneration slow (wlds) strain (Lunn et al., 1989) . In simple terms, Wallerian degeneration can be described as the demise of axonal processes distal from the cell body to a site of nerve crush. Axons of wlds mice survive a nerve crush far longer than those of wild-type mice. The wlds gene was positionally cloned in the 1990s and found to exist as a triplicated fusion gene encoding the first 70 amino acids of Ufd2a, a ubiquitin-chain assembly factor, linked directly to the complete coding sequence of NMNAT1 (Coleman et al., 1998; Conforti et al., 2000; Mack et al., 2001) . Whereas NAMPT initiates salvage from nicotinamide, NMNAT1 is one of three enzymes that convert the NMN intermediate into NAD.
In a seminal paper published in 2004 in Science, Dr. Jeff Milbrandt and colleagues provided evidence that the wlds phenotype can be attributed primarily to the overexpression of NMNAT1 (Araki et al., 2004) . The closing sentence of their manuscript is unusually prescient, reading ''It is possible that the alteration of NAD levels by manipulation of the NAD biosynthetic pathway, Sir2 protein activity, or other downstream effectors will provide new therapeutic opportunities for the treatment of diseases involving axonopathy and neurodegeneration.'' We offer the conclusion that this is exactly what active variants of the P7C3 category of neuroprotective drugs do-they enhance the intracellular production of NAD by agonizing the activity of the rate-limiting enzyme in the NAD salvage pathway.
It has recently been reported that NAD production attenuates as a function of aging in the hippocampus of rodents (Stein and Imai, 2014) . The latter study further reported age-related decline in the expression of NAMPT in the hippocampus, along with evidence that selective elimination of the NAMPT gene in neuronal stem cells significantly impairs hippocampal neurogenesis. Now that we understand that active members of the P7C3 class of compounds function by enhancing the activity of the NAMPT enzyme, the observations of Stein and Imai lend credibility to our original discovery of P7C3 as a chemical stimulant of hippocampal neurogenesis.
In addition to offering progress toward an understanding of the mode of action of the P7C3 class of neuroprotective chemicals, this work also points to a number of important, unanswered questions. First and foremost, where on the NAMPT enzyme do our chemicals bind, and how do they facilitate agonistic activation? Given that there are only about a dozen known examples of allosteric chemical activators of enzymes (Zorn and Wells, 2010) , understanding the mechanism of NAMPT activation by P7C3 represents an important challenge for future studies. Second, why is it that covalent binding of P7C3-S326 causes NAMPT to migrate in an anomalous manner in SDS-PAGE gels? Third, is it indeed the case that NAD levels may be compromised as a function of nerve cell injury or neuronal dysfunction as a consequence of neurodegenerative disease? Fourth, might NAMPT be regulated in vivo by an endogenous metabolite that is either mimicked or counteracted by active variants of the P7C3 class of neuroprotective chemicals? Fifth, is it possible that the modest levels of compound-elevated activation of the purified, recombinant NAMPT enzyme can account for the full in vivo efficacy of active variant of the P7C3 class of neuroprotective chemicals? Several arguments may be invoked to speculate on this question. For example, it is possible that P7C3 displaces the function of an inhibitory metabolite within the cell or that the native NAMPT enzyme is regulated by posttranslational modification, intracellular localization, or any of a wide spectrum of variables not reconstituted in the context of the purified, recombinant enzyme.
We close with two observations that may or may not be related. Studies of aged mice have led to the reported decline in tissue NAD levels and that certain aspects of age-related decline in overall health can be reversed by nutritional supplementation of NMN (Gomes et al., 2013) . In our initial studies of P7C3, we reported compound-mediated abrogation in cognitive decline in aged Fisher rats (Pieper et al., 2010) . Included in such studies was the unanticipated observation that compound-treated rats maintained body weight relative to the frailty of vehicle-treated controls. These distinct studies offer the possibility of considering the P7C3 class of neuroprotective chemicals as potential treatments for generalized frailty typical of aged animals and humans.
EXPERIMENTAL PROCEDURES Neurogenesis Measurement
Neurogenesis in mouse hippocampus was measured as previously described (Pieper et al., 2010) . The animal experiments were approved by the University of Texas Southwestern Medical Center Institutional Animal Care and Use Committee.
Cell Culture
Osteosarcoma cell line U2OS cells were grown in Dulbecco's modified Eagle's medium (Sigma) supplemented with 10% fetal bovine serum (FBS). Lung cancer cell line H2122 cells were cultured in RPMI-1640 medium (HyClone) supplemented with 5% FBS. These adherent cell lines were cultured employing standard procedures.
Cell Survival Assay
Cell survival assay was performed in 96-well plates using CellTiter-Glo Luminescent Cell Viability Assay kit (Promega) that measures cellular ATP content. The CellTiter-Glo reagent was diluted by adding two volumes of PBS containing 1% Triton X-100. Fifty microliters of diluted reagent was directly added to 100 ml of cell culture medium per well. The plates were incubated at room temperature for 10 min. Luminescence was recorded by Tecan SPECTRAFluor Plus reader (Tecan). Cell survival was presented as the percentage of viable cells compared with untreated control, and mean ± SD was calculated from duplicates. The dox-tox assay of P7C3 analogs was carried out in the HTS Core (University of Texas Southwestern Medical Center) using EnVison multimode plate reader (PerkinElmer).
Chemical Synthesis of Photocrosslinking Probe P7C3-S326
N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-4-(4-(prop-2-yn-1-yloxy) benzoyl)benzamide (P7C3-S326). (A) P7C3-A20 was incubated at indicated concentrations in a reaction coupled with three enzymes: NAMPT, NMNAT, and ADH (Experimental Procedures). NAMPT activity was recorded for the indicated period of time at OD340 nm by measuring NADH appearance, leading to the indicated concentration-time plot. Each assay was repeated three independent times with similar results. See also Figure S6. (B) Analysis of the activities of 30 P7C3 analogs was performed to assess their effects on NAMPT enzymatic activity. The reaction rate was calculated as the slope of the concentration-time curve.
Relative reaction rate was normalized by the control reaction run prior to compound addition. Data represent the mean of experimental duplicates. Scatter graphs were plotted to compare the ability of compounds to activate NAMPT relative to their ability to compete away P7C3-S326 crosslinking (top scatterplot), ability to protect cells from doxorubicin-mediated toxicity (middle scatterplot), or ability to facilitate NAD restoration in doxorubicin-treated cells (bottom scatterplot). Significant correlations were observed from all three sets of data. See also Table S1 .
(C) Comparison of P7C3-S243 enantiomers showed that (À)-P7C3-S243 was superior to (+)-P7C3-S243 in activating the purified NAMPT enzyme. Data are expressed as mean ± SD of duplicate independent assays. See also Figure S7 .
3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropan-1-amine (Naidoo et al., 2014; 40 .2 mg; 0.10 mmol) was added to a solution of 4-(4-(prop-2-yn-1-yloxy)benzoyl)benzoic acid (Bandyopadhyay and Bong, 2011; 28.5 mg; 0.10 mmol) , N-(3-dimethylaminopropyl)-N 0 -ethylcarbodiimide hydrochloride (21.2 mg; 0.11 mmol), and 1-hydroxybenzotriazole hydrate (15.0 mg; 0.11 mmol) in dimethylformamide (0.4 ml). The reaction went to completion within 1 hr. The mixture was diluted with EtOAc and washed several times with water and then brine. The organic layer was dried over Na 2 SO 4 , filtered, and condensed to give a light brown solid in 90% yield. 1H nuclear magnetic resonance (NMR) signals in acetone-d6 at 400 MHz were as follows: d 8.41 (dd, J = 2.0, 0.6 Hz, 2H), 8.07 (d, J = 8.4 Hz, 2H), 7.82 (dd, J = 10.3, 8.6 Hz, 4H), 4H), 7.16 (d, J = 8.9 Hz, 2H), 1H), 4.94 (d, J = 2.4 Hz, 2H), 1H), 4.82 (d, J = 5.4 Hz, 1H), 1H), 1H) , and 3.17 (t, J = 2.4 Hz, 1H). 13C NMR signals in CD2Cl2 at 100 MHz were as follows: 194.6, 167.3, 161.7, 141.4, 140.1, 136.9, 132.8, 130.7, 130.2, 129.7, 127.3, 124.1, 123.6, 114.9, 113.0, 111.2 (JC-F = 1.9 Hz), 92.1 (JC-F = 176.2 Hz), 78.2, 76.3, 56.4, 
Attachment of Fluorescent Tags via CUAAC CLICK Reaction
For copper-catalyzed azide-alkyne cycloaddition (CUAAC) CLICK reactions, 43 ml of SDS lysate was mixed with 3 ml of 1.7 mM Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine, 2 ml of 50 mM CuSO4, 1 ml of 50 mM Tris(2-carboxyethyl)phosphine, and 1 ml of 1.25 mM Alexa 532 azide. The reaction was incubated at room temperature with constant agitation at 1,000 rpm on a thermomixer (Eppendorf) for 1 hr. Afterward, samples were mixed with SDS sample-loading buffer and loaded on an 8% SDS-PAGE gel, separated, and imaged using a Typhoon imager (filter settings: excitation 533 nm, emission 555 nm, and high sensitivity).
In Vivo Binding Competition Assay H2122 cells were incubated with the S326 (0.3 mM) in the absence or presence of 5 mM P7C3 analogs for 2 hr following by UV crosslinking in vivo. Cells were lysed in 1% SDS lysis buffer, and lysates were conjugated to the fluorescent Alexa 532 dye using CLICK reaction. The samples were run on SDS-PAGE, and the gel was scanned using a Typhoon Imager. The p70 band intensity was analyzed and quantified by Image J, and the relative intensity in each assay was normalized to that of the DMSO control.
2D Gel Electrophoresis
H2122 cells were incubated with S326 (0.3 mM) in the absence or presence of 5 mM of the active analog A20 for 2 hr followed by UV crosslinking in vivo. Cells were dissolved in 1% SDS lysis buffer, and protein concentration was quantified by the bicinchoninic acid assay. For CLICK reactions, 1 mg of lysates prepared from S326-treated cells were reacted with Alexa 532 azide (red), and 1 mg of lysates from S326-and A20-treated cells were reacted with Cy5 azide (green). After the CLICK reaction, the two lysates were combined together, mixed with four volumes of acetone, and incubated at À20 C overnight.
Precipitated proteins were collected by centrifugation at 8,000 g, 15 min, 4 C. After two washes with acetone, the pellet was air dried and resuspended in 500 ml of 2D rehydration buffer (8 M urea, 2% 3-[(3-cholamidopropyl) . For 2D gel electrophoresis, 500 mg of proteins were loaded onto IPG strip of 24 cm (pH 3-10) linear (GE Healthcare) by passive rehydration using rehydration chamber for overnight at room temperature. Isoelectric focusing was conducted on an IPG Phor3 manifold (GE Healthcare) with the following protocol: 100 V for 3 hr, 300 V for 2 hr, 500 V for 3 hr (step-and-hold); 1,000 V for 1 hr (gradient); 8,000 V for 3 hr (gradient); and 8,000 V for 4 hr (step-and-hold) with total 42,000 V/hr. After isoelectric focusing, the strip was equilibrated for 15 min in equilibration buffer I (6 M urea, 2% SDS [w/v] [v/v] , and 250 mM iodoacetamide) for 15 min. Proteins were separated in the second dimension on 7.5% SDS-PAGE using Ettan Daltsix unit (GE Healthcare) at a constant current of 40 mA/gel for 5 to 6 hr at 100 W. Gel images were scanned at a resolution of 100 mm on Typhoon FLA9500 scanner using default settings for CyDyes (GE Healthcare) and preprocessed using Image Quant TL software v8.1 (GE Healthcare). Cropped gel images were analyzed using DeCyder2D Differential Analysis Software v7.1 (GE Healthcare) to detect, normalize, and quantify the protein features in the images. The P7C3-A20-competed green spots and several background spots were identified and robotically excised by an Ettan Spot Picker (GE Healthcare).
Mass Spectrometry for Protein Identification
Gel pieces were washed using 50 mM triethylammonium bicarbonate (TEAB) (pH 8.0) in 50% (v/v) acetonitrile followed by reduction with 20 mM DTT and alkylation with 55 mM iodoacetamide. Gel pieces were dehydrated using 100% (v/v) acetonitrile, air dried, and then rehydrated in the presence of 250 ng of sequencing grade trypsin (Sigma) in 50 mM TEAB. Digests were allowed to proceed overnight at 37 C. Mass spectrometry was performed using Q Exactive mass spectrometers (Thermo Fischer; Bremen), coupled to identical Ultimate 3000 RSLCnano HPLC systems (Dionex). Peptides were loaded onto a 75 mm inner diameter 3 50 cm Thermo Scientific EasySpray column packed with 2 mm resin. A 40 min linear gradient of 1%-28% acetonitrile in 0.1% formic acid followed by a 10 min ramp to 98% acetonitrile, using a flow rate of 350 nl/min, was employed to elute peptides from the column. The Easy Spray column was heated to 55 C using the integrated heater. Higher-energy C-trap dissociation analyses were performed on the Q Exactive instrument using a data-dependent top 20 method, with the full mass spectrometry (MS) scans acquired at 70 K resolution (at m/z 200) and MS/MS scans acquired at 17.5 K resolution (at m/z 200). The underfill ratio was set at 0.1%, with a 3 m/z isolation window and fixed first mass of 100 m/z for the MS/MS acquisitions. Charge exclusion was applied to exclude unassigned and charge 1 species, and dynamic exclusion was used with duration of 15 s.
Measurement of Intracellular NAD Abundance
By Liquid Chromatography-MS Cellular metabolites were extracted using 50% methanol by multiple freezethaw cycles. The cleared metabolites were dried in a Speed-Vac. The dried materials were dissolved in 0.1% formic acid and subjected to mass spectrometric analysis using a specific method developed for NAD. Relative intracellular NAD levels (NAD ion counts divided by total ion counts) were used for intersample comparisons.
By NAD/NADH-Glo Assay Kit
The assay was performed following the manufacturer's protocol (Promega). NAD/NADH-Glo reagent contains the NAD cycling enzyme that converts NAD+ to NADH. In the presence of NADH, the enzyme reductase reduces a proluciferin reductase substrate to form luciferin. Cells were grown in 96-or 384-well plates. Fifty microliters or 15 ml of NAD/NADH-Glo Detection Reagent were added to each well. The resulting luminescence signals were measured by Tecan plate reader or EnVison multimode plate reader (PerkinElmer).
Nicotinamide Flux Analysis with 14 C-Labeled Nicotinamide
Logarithmically growing cells cultured in 6-well plates were treated with doxorubicin (0.5 mM) for 48 hr. Afterward, 1 ml of 0.5 mCi/ml 14 C nicotinamide (specific activity: 50 mCi/mmol; American Radiolabeled Chemicals) were added per well. The cells were then washed once with PBS and collected by trypsin digestion. Metabolites were extracted from cells with 50 ml of perchloric acid (0.5 M) by incubating on ice for 20 min. The extracts were then neutralized with 13.75 ml of KCl/KOH (0.5 M/2.0 M) and centrifuged at 2500 3 g for 10 min at 4 C. Ten microliters of extracted metabolites were separated and identified using silicon thin-layer chromatography plates with 1 M ammonium acetate:ethanol (3:7) as solvent. For autoradiography, the chromatograms were exposed to storage Phospho screen for 3 days. Afterward, the screen was scanned using the Typhoon scanner and the 14 C-labeled compounds were quantified using Image J.
In Vitro NAMPT Assay The NAMPT activity was determined by a coupled enzyme spectrometric assay as described by Khan et al. (2006) with minor modifications. Briefly, NAMPT first converted nicotinamide to NMN, which was followed by sequential production of NAD via the NMNAT. NAD was then reduced to NADH by alcohol dehydrogenase (Sigma) using alcohol as the substrate. The resulting NADH was monitored by optical density (OD) 340 nm. Human NAMPT and NMNAT were overexpressed in E. coli and purified as described by Wang et al. (2006) and Zhou et al. (2002) , respectively. The reaction mixture contained 50 mM Tris (pH 8.0), 0.4 mM phosphoribosylpyrophosphate (Sigma), 2.5 mM ATP, 12 mM MgCl 2 , 1.5% (v/v) ethanol, 10 mM semicarbazide (Sigma), 0.02% (w/v) BSA, 2.4 mg/ml NMNAT, 0.4 unit alcohol dehydrogenase, 1 mM NAMPT, and 150 mM nicotinamide. Ten micromolar P7C3 analogs in DMSO were further diluted in ethanol prior to applying to the reaction. To minimize variation, a control reaction was run in each assay prior to compound addition.
Statistics
The correlation data analysis was performed in GraphPad Prism 6. 
